N/A N=89 Targeting Reconsolidation to Prevent Return of Fear
Fear of Flying
Primary: Fear of Flying Inventory (FFI) — 65.55; 76.57 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
Phase 3 N=51 Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.
Postpartum Hemorrhage
Primary: Total Estimated Blood Loss — 512; 634 ml
Phase 1 N=48 Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
Healthy
Primary: Population Mean Estimate for Bioavailability Following Subcutaneous (SC) Administration — 0.751 percentage of drug
Phase 3 N=33 Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
Cystic Fibrosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 24; 6; 5 participants
Phase 2 N=27 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Small Cell Carcinoma
Primary: Tumor Response — 7.4 percentage of participants
N/A N=9 Self-Defense Training in Women With Trauma
Depression · Anxiety · Stress Disorders, Post-Traumatic
Primary: Change in Self-efficacy From Baseline to Post-treatment — 23.38; 29.63 units on a scale — p=<.01
Phase 2 N=195 Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
HIV
Primary: Safety: Grade 2 or Higher Adverse Events — 64; 61; 56 participants — p=0.88
N/A N=21,752 Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies
Diabetes Mellitus · Cardiovascular Disease
Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001
Phase 2 N=40 Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC
Non Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) — 19.4 months
N/A N=48 A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization
Nosocomial Infections · Pneumonia, Ventilator-Associated
Primary: Mean Difference in Bacterial Colonization of the Nasal Prong After 18 Hours of Device Usage When Comparing the CytaCoat Nasal Prong to the Reference Device. — 8.29…
N/A N=48 The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems
Myopia
Primary: Conjunctival Hyperaemia — 0.84; 0.87; 0.87; 0.87 units on a scale
N/A N=50 Omega-3 Dietary Supplements in Schizophrenia
Schizophrenia · Schizophreniform Disorder · Schizoaffective Disorder
Primary: Treatment Response — 41.64; 42.38; 22.5868; 27.2235 units on a scale — p=0.0493
N/A N=175 Study Two on the Effectiveness of Mindfulness Training for Smokers
Nicotine Dependence
Primary: Smoking Abstinence — 17; 12 participants — p=0.35
N/A N=15 Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Graft vs Host Disease
Primary: Clinical Response of Patients With Refractory Chronic GVHD Based on the Working Group Report 2006. — 100; 78; 80 percentage of participants